Literature DB >> 29296898

Disease control should be the goal of therapy for WM patients.

Efstathios Kastritis1, Meletios A Dimopoulos1.   

Abstract

Publisher's Note:This article has a companion.

Entities:  

Year:  2017        PMID： 29296898      PMCID： PMC5729615          DOI： 10.1182/bloodadvances.2017005645

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


  22 in total

Review 1.  Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

Authors:  Robert A Kyle; Steven P Treon; Raymond Alexanian; Bart Barlogie; Magnus Björkholm; Madhav Dhodapkar; T Andrew Lister; Giampaolo Merlini; Pierre Morel; Marvin Stone; Andrew R Branagan; Véronique Leblond
Journal:  Semin Oncol       Date:  2003-04       Impact factor: 4.929

2.  Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy.

Authors:  Efstathios Kastritis; Marie-Christine Kyrtsonis; Pierre Morel; Maria Gavriatopoulou; Evdoxia Hatjiharissi; Argirios S Symeonidis; Amalia Vassou; Panagiotis Repousis; Sossana Delimpasi; Anastasia Sioni; Evrydiki Michalis; Michail Michael; Elina Vervessou; Michael Voulgarelis; Costantinos Tsatalas; Evangelos Terpos; Meletios A Dimopoulos
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

Review 3.  Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia.

Authors:  Véronique Leblond; Efstathios Kastritis; Ranjana Advani; Stephen M Ansell; Christian Buske; Jorge J Castillo; Ramón García-Sanz; Morie Gertz; Eva Kimby; Charalampia Kyriakou; Giampaolo Merlini; Monique C Minnema; Pierre Morel; Enrica Morra; Mathias Rummel; Ashutosh Wechalekar; Christopher J Patterson; Steven P Treon; Meletios A Dimopoulos
Journal:  Blood       Date:  2016-07-18       Impact factor: 22.113

4.  Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial.

Authors:  Morie A Gertz; Rafat Abonour; Leonard T Heffner; Philip R Greipp; Hajime Uno; S V Rajkumar
Journal:  Br J Haematol       Date:  2009-09-14       Impact factor: 6.998

5.  Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia.

Authors:  Steven P Treon; Guang Yang; Christine Hanzis; Leukothea Ioakimidis; Sigitas J Verselis; Edward A Fox; Lian Xu; Zachary R Hunter; Hsiuyi Tseng; Robert J Manning; Christopher J Patterson; Patricia Sheehy; Barry Turnbull
Journal:  Br J Haematol       Date:  2011-05-12       Impact factor: 6.998

6.  High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  Charalampia Kyriakou; Carmen Canals; David Sibon; Jean Yves Cahn; Majid Kazmi; William Arcese; Karin Kolbe; Norbert Claude Gorin; Kristy Thomson; Noel Milpied; Dietger Niederwieser; Karel Indrák; Paolo Corradini; Anna Sureda; Norbert Schmitz
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

7.  Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).

Authors:  Meletios A Dimopoulos; Ramón García-Sanz; Maria Gavriatopoulou; Pierre Morel; Marie-Christine Kyrtsonis; Eurydiki Michalis; Zafiris Kartasis; Xavier Leleu; Giovanni Palladini; Alessandra Tedeschi; Dimitra Gika; Giampaolo Merlini; Efstathios Kastritis; Pieter Sonneveld
Journal:  Blood       Date:  2013-09-04       Impact factor: 22.113

8.  Progression in smoldering Waldenstrom macroglobulinemia: long-term results.

Authors:  Robert A Kyle; Joanne T Benson; Dirk R Larson; Terry M Therneau; Angela Dispenzieri; Shaji Kumar; L Joseph Melton; S Vincent Rajkumar
Journal:  Blood       Date:  2012-03-26       Impact factor: 22.113

9.  Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenström’s macroglobulinemia. Results of a retrospective analysis of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.

Authors:  Alice Garnier; Marie Robin; Fabrice Larosa; Jean-Louis Golmard; Steven Le Gouill; Valérie Coiteux; Reza Tabrizi; Claude-Eric Bulabois; Victoria Cacheux; Mathieu Kuentz; Brigitte Dreyfus; Peter Dreger; Bernard Rio; Marie-Pierre Moles-Moreau; Karin Bilger; Jacques-Olivier Bay; Véronique Leblond; Didier Blaise; Olivier Tournilhac; Nathalie Dhédin
Journal:  Haematologica       Date:  2010-01-15       Impact factor: 9.941

10.  Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenström macroglobulinemia.

Authors:  B T Gaudette; B Dwivedi; K S Chitta; S Poulain; D Powell; P Vertino; X Leleu; S Lonial; A A Chanan-Khan; J Kowalski; L H Boise
Journal:  Oncogene       Date:  2015-04-20       Impact factor: 9.867
View more
  3 in total

1.  Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up.

Authors:  Jorge J Castillo; Kirsten Meid; Catherine A Flynn; Jiaji Chen; Maria G Demos; Maria L Guerrera; Amanda Kofides; Xia Liu; Manit Munshi; Nicholas Tsakmaklis; Christopher J Patterson; Guang Yang; Zachary Hunter; Steven P Treon
Journal:  Blood Adv       Date:  2020-08-25

2.  Rituximab-based combination therapy in patients with Waldenström macroglobulinemia: a systematic review and meta-analysis.

Authors:  Yan-Hua Zheng; Li Xu; Chun Cao; Juan Feng; Hai-Long Tang; Mi-Mi Shu; Guang-Xun Gao; Xie-Qun Chen
Journal:  Onco Targets Ther       Date:  2019-04-11       Impact factor: 4.147

3.  Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia.

Authors:  Steven P Treon; Kirsten Meid; Joshua Gustine; Guang Yang; Lian Xu; Xia Liu; Christopher J Patterson; Zachary R Hunter; Andrew R Branagan; Jacob P Laubach; Irene M Ghobrial; M Lia Palomba; Ranjana Advani; Jorge J Castillo
Journal:  J Clin Oncol       Date:  2020-09-15       Impact factor: 44.544
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.